Overexpression of the PSAT1 Gene in Nasopharyngeal Carcinoma Is an Indicator of Poor Prognosis

doi:10.7150/jca.15258

Chia Nan University of Pharmacy & Science Institutional Repository > 藥理學院 > 保健營養系(所) > 期刊論文 > Item 310902800/31038

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/31038

標題:	Overexpression of the PSAT1 Gene in Nasopharyngeal Carcinoma Is an Indicator of Poor Prognosis
作者:	Liao, Kuang-Ming Chao, Tung-Bo Tian, Yu-Feng Lin, Ching-Yih Lee, Sung-Wei Chuang, Hua-Ying Chan, Ti-Chun Chen, Tzu-Ju Hsing, Chung-Hsi Sheu, Ming-Jen Li, Chien-Feng
貢獻者:	Chi Mei Med Ctr, Dept Internal Med Yuans Gen Hosp, Dept Colorectal Surg Meiho Univ, Dept Hlth Business Adm Chi Mei Med Ctr, Div Gen Surg Chia Nan Univ Pharm & Sci, Dept Hlth & Nutr Chi Mei Med Ctr, Dept Internal Med Southern Taiwan Univ Sci & Technol, Dept Leisure Recreat & Tourism Management Chi Mei Med Ctr, Dept Radiat Oncol Chi Mei Med Ctr, Dept Pathol Chi Mei Med Ctr, Dept Anesthesiol Natl Hlth Res Inst, Natl Inst Canc Res Southern Taiwan Univ Sci & Technol, Dept Biotechnol
關鍵字:	PSAT1 Nasopharyngeal carcinoma prognosis trials
日期:	2016
上傳時間:	2018-01-18 11:40:22 (UTC+8)
出版者:	Ivyspring Int Publ
摘要:	Purpose: Nasopharyngeal carcinoma (NPC) is a common cancer in southern China and Southeast Asia, but risk stratification and treatment outcome in NPC patients remain suboptimal. Our study identified and validated metabolic drivers that are relevant to the pathogenesis of NPC using a published transcriptome. Phosphoserine aminotransferase 1 (PSAT1) is an enzyme that is involved in serine biosynthesis, and its overexpression is associated with colon cancer, non-small cell lung cancer and breast cancer. However, its expression has not been systemically evaluated in patients with NPC. Materials and Methods: We evaluated two public transcriptomes of NPC tissues and benign nasopharyngeal mucosal epithelial tissues that deposited in the NIH Gene Expression Omnibus database under accession number GSE34574 and GSE12452. We also performed immunohistochemical staining and assessment of PSAT1 in a total of 124 NPC patients received radiotherapy and were regularly followed-up until death or loss. The endpoints analyzed were local recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), disease-specific survival (DSS), and overall survival (OS). Results: We retrospectively evaluated 124 patients with NPC and found that high PSAT1 expression was associated with poor prognosis of NPC and indicator of advanced tumor stage. High PSAT1 expression also correlated with an aggressive clinical course, with significantly shorter DSS (HR=2.856, 95% CI 1.599 to 5.101), DMFS (HR=3.305, 95% CI 1.720 to 6.347), LRFS (HR=2.834, 95% CI 1.376 to 5.835), and OS HR=2.935, 95% CI 1.646-5.234) in multivariate analyses. Conclusions: Our study showed that PSAT1 is a potential prognostic biomarker and higher expression of PSAT1 is associated with a poor prognosis in NPC.
關聯:	Journal of Cancer, v.7 n.9, pp.1088-1094
显示于类别:	[保健營養系(所) ] 期刊論文

文件中的档案:

档案	描述	大小	格式	浏览次数
31038.pdf		742Kb	Adobe PDF	212	检视/开启
index.html		0Kb	HTML	1163	检视/开启

在CNU IR中所有的数据项都受到原著作权保护.

TAIR相关文章

数据加载中.....